Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

GSK has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly surpassing market expectations. The fourth quarter contributed £8.1 billion, a 4% rise ...

Shares of GSK plc (NYSE:GSK – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. Six ...

Ballentine Partners LLC boosted its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 40.7% in the fourth quarter, ...

“We really became impressed with what IDRx had achieved,” GSK Chief Commercial Officer Luke Miels told Fierce Biotech in an interview ahead of the J.P. Morgan Healthcare Conference.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

chief commercial officer at GSK, said in Monday’s announcement. Just last August, IDRx raised a $120 million Series B financing led by RA Capital Management, Commodore Capital and Blackstone ...

Santander (BME: SAN) stock soared over 6% after the Spanish lender reported record annual profits for the third consecutive ...

Banco Santander (BME: SAN) shares spiked over 6% on Wednesday after the lender unveiled plans for €10 billion (£8.3 billion) ...